Search Videos

Assays offer clinicians relevant targeted therapies and clinical trials based on genomic alterations
99 views | Added Jul 17, 2013 | Rate View top rated
Share this story
PARIS – Gary A. Palmer, MD, JD, MBA, MPH, senior vice president of Medical Affairs and Commercial Development at Foundation Medicine outlines the company’s unique cancer genomic analysis for routine clinical care.
According to Palmer, the FoundationOne™ assay is intended to complement traditional cancer decision tools and expand treatment options by matching each patient with targeted therapies that may be relevant to the molecular changes in their tumor. FoundationOne™ interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge; the assay then reports each patient’s genomic profile to the physician matched with targeted therapies and clinical trials that may be relevant based on the molecular blueprint of their tumor.
View more stories like this
home (1062)
Be the first to comment. Please sign in to add your thoughts below.
Related Videos
This collection is currently empty.